Expanded ACT for Psychedelic-Assisted Therapy
An Integrative Approach to Systemic Change Using Neuroscientifically Informed & Trauma-Focused ‘Parts’ Work
A two-plus-five-day training experience to learn a new integral model of psychedelic-assisted therapy
Online
February 19th-20th, 2026
9 AM — 5:30 PM EST
In Person
Centered, PLLC
March 2nd-6th, 2026
285 Nicoll St., Ste. 104, New Haven, CT 06513
Follow-Up Supervision
Fortnightly for 3 months
For psychedelic practitioners and psychedelic-curious practitioners including:
Mental health professionals, physicians, physician assistants, nurses, nurse practitioners, licensed professional counselors, social workers, and psychologists.
There exists a rapidly expanding need for qualified psychedelic practitioners who are trained in scientifically grounded, deep therapeutic approaches
One approach to psychedelic treatment is to view psychedelic medications as a standard medical intervention that improves lives with or without deep work.
Another emerging approach considers that psychedelic medications open a window for therapeutic interventions that catalyze lasting change within the nervous system and entire organism. This approach requires a deep understanding of the art and science of psychedelics and psychotherapy. This training embraces this deeper, more sophisticated framework.
We will educate trainees in a comprehensive framework that will enable them to recognize opportunities and safely target interventions at the moment patients are ready for transformation. The training will focus on ketamine and psilocybin assisted therapy, but we will address other psychedelics as well.
There will be both didactic and experiential elements. For those who meet medically appropriate indications and safety qualifications, ketamine will be offered as an educational experience under close medical and psychiatric supervision.
Note: this program is a joint venture between Centered PLLC, New Haven and Mindfulness Training LTD, London.
Registration is in British Sterling Pound GPB.
About the Facilitators
Henry J. Whitfield
MSc (CBT), ACBS peer-reviewed ACT trainer, MBACP, Advanced Traumatic Incident Reduction Trainer,
Henry Whitfield is a psychotherapy trainer and psychedelic therapy researcher, having collected years of data through psychedelic retreats that explored new ways of combining psychotherapy processes with psilocybin. He is an Association of Contextual Behavioural Science (ACBS) Peer-reviewed Acceptance and Commitment Therapy trainer, an Accredited Advanced TIR (PTSD therapy) Trainer and Cognitive Behavioural Psychotherapist (MSc – CBT), and Visiting Researcher at Regent’s University – School of Psychotherapy and Psychology.
For over seven years Henry ran and supervised brief therapy for PTSD projects for Victim Support and Mind in London gun crime hot spots, using CBT and TIR. Henry has also trained over 1500 psychological therapists since 2003, supervising mental health professionals in the NHS for ACT and Trauma work. He lead the development of new ways to learn ACT skills efficiently, offering one of the first ACT skills programs ever in 2007. He is also a passionate integral thinker, publishing journal articles and book chapters on the integration of therapeutic models including, REBT-mindfulness, ACT-TIR-CBT, Person-centred-TIR. His psychedelic plant medicine path and ACT leanings helped him to work on collapsing the polarities that divide our field such as 'psychodynamic' vs 'cognitive-behavioural'. He has written, co-written and edited training manuals for ACT, TIR and FAP (relational psychodynamic). Now he focuses his research on understanding pathways to lasting psychotherapeutic change through all phases of psychedelic therapy. He is also author of a new model of psychological flexibility A Spectrum of Selves, tailored to a psychedelic therapy context published 2021 in Frontiers in Psychiatry.
Dr. Robert Krause
Robert Krause DNP APRN-BC is the founder and Director of Clinical Services at Centered PLLC in New Haven, CT. His work involves clinical practice, education and research. He has been in practice for 27 years currently treating adults with a wide range of presentations from those with seriously and persistently mental illness, trauma, depression, and comorbid diagnosis to couples and families.
As an educator Dr Krause has been faculty at the Yale’s Schools of Medicine and Nursing, Quinnipiac University, Western Connecticut State University, and The Graduate Institute. He has also precepted graduate students in psychiatric nursing, and in professional counseling. He is currently a faculty member on a massive online course called “Addiction Treatment: Clinical Skills for Healthcare Providers” that has enrolled 75,000 students to date. He has facilitated or co-facilitates trainings for Ketamine Assisted Therapy including assisting Dr Phil Wolfson in a Ketamine training earlier this year. He has also contributed to the development of the Expanded ACT training for psychedelic therapy with Henry Whitfield. Additionally, he has supervised therapists for ketamine assisted therapy and has supervised therapists providing psychedelic therapy using psilocybin analogs for the Embark program of Cybin pharmaceuticals.
Dr. Krause has been trained in and utilizes a number of different therapeutic modalities including Trauma therapy (certificate from Harvard University), Acceptance and Commitment Therapy (ACT), Trauma Incident Reduction (TIR), Sex therapy (certificate from CIIS) and Psychedelic therapy ( from CIIS), Ketamine Assisted Therapy (Ketamine Training Center). He is a MAPS therapist.
Dr Krause was a co-author of Yale’s Manual for Psilocybin Assisted Therapy and was a therapist with the Psilocybin induced neuroplasticity in the treatment of Major Depressive Disorder at the Yale School of Medicine. Among publications he has co-authored are:
Dr. Mark Landreneau
Mark Landreneau received his MD from Columbia University College of Physician and Surgeons and subsequently completed a neurology residency and neurocritical care fellowship at Yale-New Haven Hospital. He has worked as faculty in the department of neurology at Yale University and now maintains a practice at Centered focusing on neuropsychiatric disorders in addition to his neurohospitalist practice at Yale.
He has significant experience and skill treating life threatening injuries of the nervous system including brain injuries that cause disorders of consciousness. He has written multiple articles and book chapters on severe strokes, brain death, and novel treatments for brain and spinal injuries. Over time he developed a particular interest in mood disorders related to neurological illness as well as mood disorders more generally, particularly in the context of neuroplastogens and psychedelics.
He brings a background using multimodal monitoring in the ICU–integrating noninvasive and invasive monitoring such as EEG, advanced neuroimaging, and novel neurophysiological monitors. Using insights from recent clinical trials and basic science studies on psychedelics, he has a deep interest in integrating the neurophysiology of psychedelics with psychotherapy in order to maximize treatment effects from this powerful class of medications.
At the moment, his focus is on ketamine assisted therapy, learning and integrating cutting edge developments in the field into his practice. His approach is informed by an emerging neuroscientific model of circuits and networks, viewing this as inseparable from subjective experience, where humanistic traditions have studied the mind for thousands of years.